Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap19.47B
Market cap19.47B
Price-Earnings ratio13.12
Price-Earnings ratio13.12
Dividend yield—
Dividend yield—
Average volume1.26M
Average volume1.26M
High today$134.42
High today$134.42
Low today$132.21
Low today$132.21
Open price$133.49
Open price$133.49
Volume619.89K
Volume619.89K
52 Week high$238.00
52 Week high$238.00
52 Week low$110.04
52 Week low$110.04
BIIB News
TipRanks 3d
Biogen’s Litifilimab Study: A Long-Term Look at SLE TreatmentBiogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...
Analyst ratings
49%
of 37 ratingsBuy
48.6%
Hold
48.6%
Sell
2.7%
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.